Home » Market News » DirectorsTalk Highlights » Affimer technology
Avacta Group Plc

Affimer technology

Developing the next generation of biotherapeutics

Affimer® technology is a novel class of biotherapeutic based on a naturally occurring human protein called Stefin A.

Avacta is building a pipeline of clinically differentiated cancer immunotherapies leveraging the key benefits of Affimer® technology. Our aim is to extend the benefits of cancer immunotherapies to all patients, including those who do not experience a durable response to current single immune checkpoint inhibitors.

The Affimer® platform is Avacta’s proprietary therapeutic platform with its intellectual property covered by several patent families.

Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs a

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.